Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kay S. Arnold is active.

Publication


Featured researches published by Kay S. Arnold.


Metabolism-clinical and Experimental | 1984

Receptor binding activity of high-density lipoproteins containing apoprotein E from abetalipoproteinemic and normal neonate plasma

Thomas L. Innerarity; Thomas P. Bersot; Kay S. Arnold; K H Weisgraber; Paul Davis; Trudy M. Forte; Robert W. Mahley

The receptor binding properties of lipoproteins derived from neonates and abetalipoproteinemic patients were examined. Compared to normal adults, the neonate plasma contained reduced cholesterol levels, with only 40% of the total cholesterol transported in the low-density lipoproteins (LDL). When compared at equal cholesterol concentrations, however, the total neonate lipoproteins (d less than 1.21) were as effective as adult d less than 1.21 lipoproteins in stimulating cholesteryl ester formation in cultured human fibroblasts. Analysis of the neonate lipoproteins explained their enhanced ability to deliver cholesterol to the cells via LDL (apoprotein B,E) receptors: the neonate d = 1.02-1.063 fraction contained, in addition to LDL, alpha 2-migrating, apoprotein E-rich high-density lipoproteins (HDL1), which were isolated by Geon-Pevikon electrophoresis. In binding studies performed with human fibroblasts at 4 degrees C, the neonate HDL1 were 14-fold more effective than either neonate or adult human LDL in displacing 125I-LDL from apo-B,E receptors. The neonate HDL (d = 1.063-1.21) contained a subfraction rich in apo-E and apo(E-A-II), which was isolated by heparin-Sepharose chromatography. This fraction was also active in displacing 125I-LDL from the receptors on cultured fibroblasts. Apoprotein E-containing HDL subclasses, similar to those described in the blood of neonates, were present in the d less than 1.063 and d = 1.063-1.21 lipoprotein fractions of patients with abetalipoproteinemia. These HDL with apo-E were enriched in cholesterol and were as effective as normal LDL in competing with 125I-LDL for apo-B,E receptor-mediated binding, internalization, and degradation. When incubated with cultured human fibroblasts, the HDL with apo-E from the abetalipoproteinemic subjects increased the cholesteryl ester mass three- to fourfold. These studies suggest that neonates and abetalipoproteinemic subjects may depend (at least in part) upon lipoproteins containing apo-E to deliver cholesterol to various tissues via the LDL (apo-B,E) receptor.


Proceedings of the National Academy of Sciences of the United States of America | 1979

Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc.

Robert E. Pitas; Thomas L. Innerarity; Kay S. Arnold; Robert W. Mahley


Journal of Biological Chemistry | 1995

Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor

Richard Bucala; Robert F. Mitchell; Kay S. Arnold; Thomas L. Innerarity; Helen Vlassara; Anthony Cerami


Nature Structural & Molecular Biology | 1996

Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.

Li-Ming Dong; Sean Parkin; Sergei D. Trakhanov; Bernhard Rupp; Trey Simmons; Kay S. Arnold; Yvonne Newhouse; Thomas L. Innerarity; Karl H. Weisgraber


Journal of Lipid Research | 2000

Apolipoprotein E–low density lipoprotein receptor interaction: influences of basic residue and amphipathic α-helix organization in the ligand

Mohamed Zaiou; Kay S. Arnold; Yvonne Newhouse; Thomas L. Innerarity; Karl H. Weisgraber; Mark L. Segall; Michael C. Phillips; Sissel Lund-Katz


Nature | 1985

Platelet secretory products inhibit lipoprotein metabolism in macrophages.

David R. Phillips; Kay S. Arnold; Thomas L. Innerarity


Arteriosclerosis, Thrombosis, and Vascular Biology | 1991

Apolipoprotein B gene mutations in Austrian subjects with heart disease and their kindred.

Walter Friedl; Erwin H. Ludwig; Maureen E. Balestra; Kay S. Arnold; Bemhard Paulweber; Friedrich Sandhofer; Brian J. McCarthy; Thomas L. Innerarity


Journal of Biological Chemistry | 1991

13C NMR evidence that substitution of glutamine for arginine 3500 in familial defective apolipoprotein B-100 disrupts the conformation of the receptor-binding domain.

Sissel Lund-Katz; Thomas L. Innerarity; Kay S. Arnold; Linda K. Curtiss; Michael C. Phillips


Journal of Lipid Research | 1998

The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity

Li-Ming Dong; Thomas L. Innerarity; Kay S. Arnold; Yvonne Newhouse; Karl H. Weisgraber


Journal of Lipid Research | 1994

Isolation of allele-specific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 subjects.

Kay S. Arnold; Maureen E. Balestra; Ronald M. Krauss; Linda K. Curtiss; Stephen G. Young; Thomas L. Innerarity

Collaboration


Dive into the Kay S. Arnold's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Linda K. Curtiss

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Maureen E. Balestra

Lawrence Berkeley National Laboratory

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sissel Lund-Katz

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Anthony Cerami

Kenneth S. Warren Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge